Latest posts
-
PaxMedica to Join Fireside Chat with PCG Advisory Following Positive Top Line Results from PAX-HAT-301 Study
PaxMedica to discuss significance of Phase 3 study results Interview to be webcast on Tuesday, August 15, 2023, at 10:30 am ET TARRYTOWN, NY, August 8, 2023 – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD)